Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Biogen Inc. Drug Patent Portfolio

Biogen Inc. owns 1 purple book drug protected by 32 US patents Given below is the list of Biogen Inc.'s drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10844416 Manganese supplementation for control of glycosylation in mammalian cell culture process 01 Jun, 2036
Active
US11268119 Copper supplementation for control of glycosylation in mammalian cell culture process 21 Feb, 2036
Active
US11124760 Methods for overcoming glutamine deprivation during mammalian cell culture 27 Aug, 2035
Active
US10023831 Gas delivery devices and associated systems and methods 17 Mar, 2035
Active
US10676772 Control of protein glycosylation by culture medium supplementation and cell culture process parameters 19 Aug, 2034
Active
US9994968 Electrochemical etching apparatus 19 Aug, 2034
Active
US10119976 Method of assessing risk of PML 27 May, 2034
Active
US10677803 Method of assessing risk of PML 27 May, 2034
Active
US11280794 Method of assessing risk of PML 27 May, 2034
Active
US9562252 Methods of preventing and removing trisulfide bonds 11 May, 2033
Active
US10590454 Methods of preventing and removing trisulfide bonds 11 May, 2032
Active
US9790533 Methods of preventing and removing trisulfide bonds 11 May, 2032
Active
US9316641 Assay for JC virus antibodies 09 Jan, 2032
Active
US9109015 Method of isolating biomacromolecules using low pH and divalent cations 13 Aug, 2031
Active
US8809049 Methods for producing mammalian cells 22 May, 2031
Active
US10308706 Methods of preventing and removing trisulfide bonds 05 Feb, 2031
Active
US8318416 Nutrient monitoring and feedback control for increased bioproduct production 20 Jan, 2031
Active
US10444234 Assay for JC virus antibodies 11 Jan, 2031
Active
US11287423 Assay for JC virus antibodies 11 Jan, 2031
Active
US9096879 Method of supplementing culture media to prevent undesirable amino acid substitutions 07 Jan, 2031
Active
US9212379 Nutrient monitoring and feedback control for increased bioproduct production 28 Nov, 2030
Active
US9005926 Methods of preventing and removing trisulfide bonds 01 Oct, 2030
Active
US9696307 Methods for the detection of JC polyoma virus 05 Feb, 2030
Active
US8124350 Methods and products for evaluating an immune response to a therapeutic protein 02 Aug, 2027
Active
US9493567 Methods of treating inflammatory and autoimmune diseases with natalizumab 05 Mar, 2027
Active
US10233245 Methods of treating inflammatory and autoimmune diseases with natalizumab 28 Feb, 2027
Active
US11292845 Methods of treating inflammatory and autoimmune diseases with natalizumab 28 Feb, 2027
Active
US8871449 Methods and products for evaluating an immune response to a therapeutic protein 12 Apr, 2026
Active
US10705095 Methods and products for evaluating an immune response to a therapeutic protein 04 Apr, 2026
Active
US9709575 Methods and products for evaluating an immune response to a therapeutic protein 04 Apr, 2026
Active
US7157276 Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures 21 Jun, 2024
Active
US7759117 Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures 21 Jun, 2024
Active


Biogen Inc.'s Family Patents


Family Patents



Biogen Inc. Drug List

Given below is the complete list of Biogen Inc.'s drugs and the patents protecting them.


1. Tysabri

Tysabri is protected by 32 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10844416 Manganese supplementation for control of glycosylation in mammalian cell culture process 01 Jun, 2036
(11 years from now)
Active
US11268119 Copper supplementation for control of glycosylation in mammalian cell culture process 21 Feb, 2036
(11 years from now)
Active
US11124760 Methods for overcoming glutamine deprivation during mammalian cell culture 27 Aug, 2035
(10 years from now)
Active
US10023831 Gas delivery devices and associated systems and methods 17 Mar, 2035
(10 years from now)
Active
US10676772 Control of protein glycosylation by culture medium supplementation and cell culture process parameters 19 Aug, 2034
(9 years from now)
Active
US9994968 Electrochemical etching apparatus 19 Aug, 2034
(9 years from now)
Active
US10119976 Method of assessing risk of PML 27 May, 2034
(9 years from now)
Active
US10677803 Method of assessing risk of PML 27 May, 2034
(9 years from now)
Active
US11280794 Method of assessing risk of PML 27 May, 2034
(9 years from now)
Active
US9562252 Methods of preventing and removing trisulfide bonds 11 May, 2033
(8 years from now)
Active
US10590454 Methods of preventing and removing trisulfide bonds 11 May, 2032
(7 years from now)
Active
US9790533 Methods of preventing and removing trisulfide bonds 11 May, 2032
(7 years from now)
Active
US9316641 Assay for JC virus antibodies 09 Jan, 2032
(7 years from now)
Active
US9109015 Method of isolating biomacromolecules using low pH and divalent cations 13 Aug, 2031
(6 years from now)
Active
US8809049 Methods for producing mammalian cells 22 May, 2031
(6 years from now)
Active
US10308706 Methods of preventing and removing trisulfide bonds 05 Feb, 2031
(6 years from now)
Active
US8318416 Nutrient monitoring and feedback control for increased bioproduct production 20 Jan, 2031
(6 years from now)
Active
US10444234 Assay for JC virus antibodies 11 Jan, 2031
(6 years from now)
Active
US11287423 Assay for JC virus antibodies 11 Jan, 2031
(6 years from now)
Active
US9096879 Method of supplementing culture media to prevent undesirable amino acid substitutions 07 Jan, 2031
(6 years from now)
Active
US9212379 Nutrient monitoring and feedback control for increased bioproduct production 28 Nov, 2030
(5 years from now)
Active
US9005926 Methods of preventing and removing trisulfide bonds 01 Oct, 2030
(5 years from now)
Active
US9696307 Methods for the detection of JC polyoma virus 05 Feb, 2030
(5 years from now)
Active
US8124350 Methods and products for evaluating an immune response to a therapeutic protein 02 Aug, 2027
(2 years from now)
Active
US9493567 Methods of treating inflammatory and autoimmune diseases with natalizumab 05 Mar, 2027
(2 years from now)
Active
US10233245 Methods of treating inflammatory and autoimmune diseases with natalizumab 28 Feb, 2027
(2 years from now)
Active
US11292845 Methods of treating inflammatory and autoimmune diseases with natalizumab 28 Feb, 2027
(2 years from now)
Active
US8871449 Methods and products for evaluating an immune response to a therapeutic protein 12 Apr, 2026
(1 year, 3 months from now)
Active
US10705095 Methods and products for evaluating an immune response to a therapeutic protein 04 Apr, 2026
(1 year, 3 months from now)
Active
US9709575 Methods and products for evaluating an immune response to a therapeutic protein 04 Apr, 2026
(1 year, 3 months from now)
Active
US7157276 Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures 21 Jun, 2024
(5 months ago)
Expired
US7759117 Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures 21 Jun, 2024
(5 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tysabri's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List